MP53-03 IMPACT OF LOWER CASTRATE-LEVEL TESTOSTERONE ON PROGRESSION TO CASTRATE-RESISTANT PROSTATE CANCER FOR PATIENTS UNDERGOING CONTINUOUS ANDROGEN DEPRIVATION THERAPY: A PROSPECTIVE COHORT STUDY

• DOI: 10.1016/j.juro.2017.02.1654
• Publication Date: 2017-04-03T18:44:00Z
• Authors: Taehyoung Lee; Stuti Tanya; Bobby Shayegan
• Keywords: Enzalutamide

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) III1 Apr 2017MP53-03 IMPACT OF LOWER CASTRATE-LEVEL TESTOSTERONE ON PROGRESSION TO CASTRATE-RESISTANT PROSTATE CANCER FOR PATIENTS UNDERGOING CONTINUOUS ANDROGEN DEPRIVATION THERAPY: A PROSPECTIVE COHORT STUDY Taehyoung Lee, Stuti Tanya, and Bobby Shayegan LeeTaehyoung Lee More articles by this author , TanyaStuti Tanya ShayeganBobby View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.1654AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES We investigated whether lower testosterone threshold compared traditionally accepted level castrate-level (< 50 ng/dl) has an impact on time progression castrate-resistant prostate cancer (CRPC) in patients undergoing continuous androgen deprivation therapy (ADT). METHODS single-center, prospective review 153 consecutive ADT from 2006 2016 was performed. Patients were excluded the analysis if they received intermittent ADT, concurrent with external beam radiation therapy, or did not achieve ng/dl). Serum measured every three months after initiation ADT. categorized based their 1-year mean value 20 ng/dl, 20-32 32-50 > outcome measures compared. Progression CRPC assessed Kaplan-Meier method. Statistical performed using log-rank, Breslow, Tarone-Ware tests compare groups. RESULTS total 112 included analysis. Median age at diagnosis 67.9 (range: 50.9-89.1). follow-up 27.9 3.3-114.6). PSA prior 18 ng/mL 0.61-2940). 72.3% achieved a T < ng/dl; 18.6% 5.4% 3.6% ng/dl. There no statistically significant difference progression-free survival between different levels values (log-rank p=0.813). CONCLUSIONS The results suggest that there may be strict control beyond what is considered traditional testosterone. However, only small proportion had 32 ng/dl (9.0%). larger study reveal beneficial role reduction management advanced cancer. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e713-e714 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Expand PDF downloadLoading ...